US-based Ultragenyx Pharmaceutical has started dosing first patient in the pivotal Phase III trial of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy to treat Mucopolysaccharidosis 7 (MPS 7), also known as Sly syndrome.
The global, randomised, placebo-controlled, blind-start Phase III trial will evaluate the efficacy and safety of rhGUS in 12 patients between five and 35 years old and they will be randomised to one of four groups.
Go deeper with GlobalData
One group will begin rhGUS therapy immediately, while the other three will start first with placebo and cross over to rhGUS at different predefined time points in a blinded manner.
The company said that the new trial design generates treatment data from all 12 patients, improving the statistical power of the trial relative to a traditional parallel-group design.
Based on data from the Phase I/II trial, patients will be dosed with 4mg/kg of rhGUS every other week for up to a total of 48 weeks, and all groups will receive a minimum of 24 weeks of treatment with rhGUS.
See Also:
The trial’s primary objective is to determine the efficacy of rhGUS as determined by the reduction in urinary GAG excretion after 24 weeks of treatment.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe company has already reached an agreement with both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) on the pivotal trial design.
The agreement with FDA was reached after deciding that their evaluation of the pivotal Phase III trial will be based on the totality of the data on a patient-by-patient basis.
EMA has agreed that approval under exceptional circumstances could be possible based on a single positive Phase III trial using urinary GAG excretion as the primary endpoint with a trend toward improvement in the most important clinical endpoints.
The company intends to report data from the Phase III trial in the first half of 2016.
